ReviewMetabolites2021
Single-Cell Multiomics Analysis for Drug Discovery.
Review in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Advances in Oral Cavity Stem Cell Research Revealed through Multi-omics Analysis.Stem cell reviews and reports · 2026Review
- Review
- Navigating tumour microenvironment in endometrial carcinoma: a comprehensive review integrating immunohistochemistry, single-cell RNA-sequencing and spatial transcriptomics.Frontiers in oncology · 2025Review
- Pathogenesis and research progress of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World journal of hepatology · 2024Article
- Advances in Integrated Multi-omics Analysis for Drug-Target Identification.Biomolecules · 2024Review
- Single-cell lipidomics enabled by dual-polarity ionization and ion mobility-mass spectrometry imaging.Nature communications · 2023Article
- Liver in infections: a single-cell and spatial transcriptomics perspective.Journal of biomedical science · 2023Review
- Dissecting the brain with spatially resolved multi-omics.Journal of pharmaceutical analysis · 2023Review
- Metabolic Priming as a Tool in Redox and Mitochondrial Theragnostics.Antioxidants (Basel, Switzerland) · 2023Review
- Challenges and opportunities in NASH drug development.Nature medicine · 2023Review
- The Evolution of Single-Cell RNA Sequencing Technology and Application: Progress and Perspectives.International journal of molecular sciences · 2023Review
- Systems approaches to investigate the role of NF-κB signaling in aging.The Biochemical journal · 2022Review
- Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the heterogeneity seen in cell populations within biological systems, analysis of single cells is necessary for studying mechanisms that cannot be identified on a bulk population level. There are significant variations in the biological and physiological function of cell populations due to the functional differences within, as well as between, single species as a result of the specific proteome, transcriptome, and metabolome that are unique to each individual cell. Single-cell analysis proves crucial in providing a comprehensive understanding of the biological and physiological properties underlying human health and disease. Omics technologies can help to examine proteins (proteomics), RNA molecules (transcriptomics), and the chemical processes involving metabolites (metabolomics) in cells, in addition to genomes. In this review, we discuss the value of multiomics in drug discovery and the importance of single-cell multiomics measurements. We will provide examples of the benefits of applying single-cell omics technologies in drug discovery and development. Moreover, we intend to show how multiomics offers the opportunity to understand the detailed events which produce or prevent disease, and ways in which the separate omics disciplines complement each other to build a broader, deeper knowledge base.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.